Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline
JAC-Antimicrobial Resistance · 03.09.2024 · 6 (5)
DOI: 10.1093/jacamr/dlae141 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 05.09.2024. Verfasst von Ghady Haidar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NHLBI NIH HHS, National Institute of Allergy and Infectious Diseases of the National Institutes of Health.
Abstract (Originalsprache)
Background
Cefiderocol (FDC) or ceftazidime-avibactam with aztreonam (CZA-ATM) are frontline agents for New Delhi metallo-β-lactamase (NDM)-producing Enterobacterales; however, clinical data are scarce, and mechanisms of treatment-emergent resistance are ill-defined. Our objectives were to characterize serial isolates and stool microbiota from a liver transplant recipient with NDM-producing Escherichia coli bacteraemia.
Methods
Isolates collected pre- and post-CZA–ATM treatment underwent broth microdilution susceptibility testing and whole-genome sequencing. Longitudinal stool collected during CZA–ATM therapy underwent metagenomic sequencing (Nanopore MinION).
Results
The baseline isolate exhibited elevated MICs for ATM–AVI (16/4 µg/mL) and FDC (8 µg/mL). Posttreatment, a rectal surveillance isolate exhibited high-level resistance to ATM–AVI (> 128/4 µg/mL) and FDC (32 µg/mL). Both isolates belonged to ST361 and harboured WT blaNDM-5. The baseline isolate contained wild type (WT) blaCMY-145 and mutations in ftsI (which encodes PBP3), including a YRIN insertion at residue 338 and the non-synonymous substitutions Q227H, E353K and I536L. The posttreatment isolate harboured new mutations in ftsI (A417 V) and blaCMY-145 (L139R and N366Y). Analysis of four stool samples collected during CZA–ATM treatment revealed high E. coli abundance. E. coli relative abundance increased from 34.5% (first sample) to 61.9% (last sample).
Conclusions
Baseline mutations in ftsI were associated with reduced susceptibility to ATM–AVI and FDC in an ST361 NDM-5-producing E. coli bloodstream isolate. High-level resistance was selected after CZA–ATM treatment, resulting in new ftsl and blaCMY-145 mutations. These findings underscore the need for ATM–AVI susceptibility testing for NDM producers, and the potential for PBP3 mutations to confer cross-resistance to ATM–AVI and FDC, which can emerge after CZA–ATM treatment.
Autor:innen und Institutionen
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Center for Innovative Antimicrobial Therapy, Division of Infectious Diseases, UPMC, Pittsburgh, PA, USA.
- Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
- Center for Medicine and the Microbiome, Division of Pulmonary, Allergy, Critical Care and Sleep Medicine, UPMC, Pittsburgh, PA, USA.
- Antibiotic Management Program, Division of Infectious Diseases, UPMC, Pittsburgh, PA, USA.
ORCID-Profile: Ryan K Shields
Förderung
- NIAID NIH HHS
- NHLBI NIH HHS
- National Institute of Allergy and Infectious Diseases of the National Institutes of Health
- National Heart, Lung, Blood Institute of the National Institutes of Health
- National Institutes of Health
Zitieren
APA
Haidar, G., Kline, E. G., Kitsios, G. D., Wang, X., Kwak, E. J., Newbrough, A., Friday, K., Hughes Kramer, K., & Shields, R. K. (2024). Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. JAC-Antimicrobial Resistance, 6(5). https://doi.org/10.1093/jacamr/dlae141
Vancouver
Haidar G, Kline EG, Kitsios GD, Wang X, Kwak EJ, Newbrough A, et al. Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline. JAC-Antimicrobial Resistance. 2024;6(5). doi:10.1093/jacamr/dlae141
BibTeX
@article{Haidar2024,
author = {Haidar, Ghady and Kline, Ellen G and Kitsios, Georgios D and Wang, Xiaohong and Kwak, Eun Jeong and Newbrough, Anthony and Friday, Kelly and Hughes Kramer, Kailey and Shields, Ryan K},
title = {Emergence of high-level aztreonam–avibactam and cefiderocol resistance following treatment of an NDM-producing Escherichia coli bloodstream isolate exhibiting reduced susceptibility to both agents at baseline},
journal = {JAC-Antimicrobial Resistance},
year = {2024},
volume = {6},
number = {5},
doi = {10.1093/jacamr/dlae141}
}
EUVIMED